0000899243-20-025444.txt : 20200916 0000899243-20-025444.hdr.sgml : 20200916 20200916204735 ACCESSION NUMBER: 0000899243-20-025444 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200916 FILED AS OF DATE: 20200916 DATE AS OF CHANGE: 20200916 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Logos Global Management LP CENTRAL INDEX KEY: 0001792126 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 201179928 BUSINESS ADDRESS: STREET 1: 1 LETTERMAN DRIVE STREET 2: STE. D3-700 CITY: SAN FRANCISCO STATE: CA ZIP: 94129 BUSINESS PHONE: 4158014660 MAIL ADDRESS: STREET 1: 1 LETTERMAN DRIVE STREET 2: STE. D3-700 CITY: SAN FRANCISCO STATE: CA ZIP: 94129 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-09-16 0 0001818794 Dyne Therapeutics, Inc. DYN 0001792126 Logos Global Management LP 1 LETTERMAN DRIVE, SUITE D3-700 SAN FRANCISCO CA 94129 0 0 1 0 Series B Preferred Stock Common Stock 804392 I See footnotes The Series B Preferred Stock is convertible into common stock on a 3.3169-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date. The reporting persons are Logos Opportunities Fund II LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William and Dr. Walmsley are controlling persons of LGM and Logos GP and managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William and Dr. Walmsley as controlling persons of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. /s/ Arsani William, Managing Partner 2020-09-16